EPISODE · Jun 9, 2020 · 42 MIN
The Magic Bullet: Dr. Saralyn Mark on COVID-19, Women's Health, and the Immune System
from Out of Patients with Matthew Zachary
Dr. Saralyn Mark, first and foremost, is a Leader of the American Medical Women’s Association (AMWA). She served as the Senior Policy Advisor to the White House Office of Science and Technology during the Obama administration working on the Ebola outbreak in 2014. At the Department of Health and Human Services and NASA, she was the first Senior Medical Advisor to the Office on Women’s Health. She joined Matthew remotely to cut through the clutter, break down some of the COVID-19 mumbo jumbo, and level-set reality a bit while the world is on fire. Check out Dr. Mark’s book Stellar Medicine: A Journey Through the Universe of Women’s Health, available wherever books are sold.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
What this episode covers
Dr. Saralyn Mark, first and foremost, is a Leader of the American Medical Women’s Association (AMWA). She served as the Senior Policy Advisor to the White House Office of Science and Technology during the Obama administration working on the Ebola outbreak in 2014. At the Department of Health and Human Services and NASA, she was the first Senior Medical Advisor to the Office on Women’s Health. She joined Matthew remotely to cut through the clutter, break down some of the COVID-19 mumbo jumbo, and level-set reality a bit while the world is on fire. Check out Dr. Mark’s book Stellar Medicine: A Journey Through the Universe of Women’s Health, available wherever books are sold. See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
NOW PLAYING
The Magic Bullet: Dr. Saralyn Mark on COVID-19, Women's Health, and the Immune System
No transcript for this episode yet
Similar Episodes
Dec 5, 2025 ·50m
Oct 9, 2025 ·33m
Oct 3, 2025 ·40m
Sep 11, 2025 ·31m
Aug 27, 2025 ·39m
Aug 18, 2025 ·54m